BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27017557)

  • 1. Rituximab in a patient with splenic marginal zone lymphoma and acquired angioedema.
    Motosue MS; Howard MT; Butterfield JH
    Ann Allergy Asthma Immunol; 2016 May; 116(5):472-3. PubMed ID: 27017557
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.
    Kalpadakis C; Pangalis GA; Sachanas S; Tsirkinidis P; Kontopidou FN; Moschogiannis M; Yiakoumis X; Koulieris E; Dimopoulou MN; Kokkoris SI; Kyrtsonis MC; Siakantaris MP; Tsourouflis G; Korkolopoulou P; Rontogianni D; Tsaftaridis P; Plata E; Papadaki HA; Panagiotidis P; Angelopoulou MK; Vassilakopoulos TP
    Blood; 2018 Aug; 132(6):666-670. PubMed ID: 29914978
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma.
    Robinson AC; Nachar VR
    J Oncol Pharm Pract; 2020 Jul; 26(5):1248-1253. PubMed ID: 31766968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.
    Ishiguro K; Sasaki Y; Takagi Y; Niinuma T; Suzuki H; Tokino T; Hayashi T; Takahashi T; Igarashi T; Matsuno Y
    Medicine (Baltimore); 2020 Aug; 99(35):e21938. PubMed ID: 32871937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Splenic marginal zone lymphoma complicated by cold agglutinin disease].
    Ochi K; Yokoyama K; Ohno N; Ota Y; Tojo A
    Rinsho Ketsueki; 2017; 58(2):132-137. PubMed ID: 28321090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
    Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
    Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splenic Marginal Zone Lymphoma with Acquired von Willebrand Syndrome Diagnosed via Splenic Bleeding.
    Komeno Y; Shibuya N; Uryu H; Yamada H; Toda T; Shibasaki M; Kunishima S; Iihara K; Ryu T
    Intern Med; 2017; 56(5):557-562. PubMed ID: 28250305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma.
    Lyu R; Wang T; Wang Y; Xiong W; Wang H; Yan Y; Wang Q; Liu W; An G; Huang W; Sui W; Xu Y; Zou D; Wang J; Qiu L; Yi S
    Br J Haematol; 2021 Sep; 194(5):862-869. PubMed ID: 34328213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.
    Kalpadakis C; Pangalis GA; Sachanas S; Rontogianni D; Korkolopoulou P; Milionis V; Vassilakopoulos TP; Papadaki HA; Angelopoulou MK
    Leuk Lymphoma; 2016 Nov; 57(11):2705-8. PubMed ID: 27082039
    [No Abstract]   [Full Text] [Related]  

  • 10. High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibitor deficiency.
    Castelli R; Wu MA; Arquati M; Zanichelli A; Suffritti C; Rossi D; Cicardi M
    Br J Haematol; 2016 Mar; 172(6):902-8. PubMed ID: 26728240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
    Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
    Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
    Philip AZ
    J Natl Compr Canc Netw; 2018 Mar; 16(3):230-233. PubMed ID: 29523661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Protein-Losing Enteropathy Due to an Indolent Splenic Lymphoma: Case Report and Review of the Literature.
    Naymagon L; Ward S; Naymagon S; Navada S
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e165-e168. PubMed ID: 30685184
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis.
    Niscola P; Palumbo R; Scaramucci L; Tendas A; Cupelli L; Giovannini M; Piccioni D; Dentamaro T; Perrotti AP; de Fabritiis P
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):759-60. PubMed ID: 18500519
    [No Abstract]   [Full Text] [Related]  

  • 15. [Successful treatment with rituximab in a patient with splenic marginal zone B-cell lymphoma accompanied by cold agglutinin disease].
    Yasuyama M; Kawauchi K; Otsuka K; Tamura H; Fujibayashi M
    Nihon Ronen Igakkai Zasshi; 2014; 51(6):569-75. PubMed ID: 25749330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Massive intrafollicular and arterial hyalinosis of the spleen following rituximab and methylprednisolone therapy in a patient with splenic marginal zone lymphoma.
    Schaefer IM; Marx A; Sauer C; Hohloch K; Ghadimi BM; Trümper L; Ströbel P
    Histopathology; 2013 Mar; 62(4):664-7. PubMed ID: 23379885
    [No Abstract]   [Full Text] [Related]  

  • 17. Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
    Demirci H; Ozgonul C; Diniz Grisolia AB; Elner VM
    Ophthalmology; 2020 Sep; 127(9):1270-1273. PubMed ID: 32336490
    [No Abstract]   [Full Text] [Related]  

  • 18. Splenic marginal zone lymphoma with monoclonal IgG: A case report.
    Zhang X; Ren S; Zhang N; Wang X; Qiu L; Sun H; Yi H; Fan F
    Medicine (Baltimore); 2024 Feb; 103(6):e37158. PubMed ID: 38335376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report.
    Arcaini L; Sacchi P; Jemos V; Lucioni M; Rumi E; Dionigi P; Paulli M
    Ann Hematol; 2009 Apr; 88(4):379-81. PubMed ID: 18709501
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined intraocular and systemic rituximab for ocular lymphoproliferative disorder with extranodal marginal zone lymphoma-type morphology after heart transplant.
    Bata BM; Pulido JS; Patel SV; Khan SP; Salomao D; Boyce TG; Bothun ED
    J AAPOS; 2018 Apr; 22(2):159-161. PubMed ID: 29408337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.